An imaging study in patients with advanced solid carcinoembryonic antigen (CEA)–positive tumors previously confirmed selective and targeted biodistribution of another IL2v fusion molecule (the CEA-IL2v agent cergutuzumab amunaleukin) in CEA-positive tumor cells (23). This evidence concerns the gene CEACAM5 and neoplasm.